Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone
C. Massard, J. Mateo, Y. Loriot, C. Pezaro, L. Albiges, N. Mehra, A. Varga, D. Bianchini, C. J. Ryan, D. P. Petrylak, G. Attard, L. Shen, K. Fizazi, J. de Bono
Dive into the research topics of 'Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone'. Together they form a unique fingerprint.